Genetic variability in the IL1RN gene and the balance between interleukin (IL)-1 receptor agonist and IL-1β in idiopathic pulmonary fibrosis

Clinical and Experimental Immunology

Volumn 166, Issue 3, 2011, Pages 346-351

  Barlo, N P ^a   Van Moorsel, C H M ^a,d   Korthagen, N M ^a   Heron, M ^a   Rijkers, G T ^b   Ruven, H J T ^c   Van Den Bosch, J M M ^a,d   Grutters, J C ^a,d  

^a Department of Pulmonology   (Netherlands)

^b Departments of Medical Microbiology and Immunology   (Netherlands)

^c ST ANTONIUS HOSPITAL   (Netherlands)

^d UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

Bronchoalveolar lavage; Idiopathic pulmonary fibrosis; Interleukin 1; Single nucleotide polymorphism

Indexed keywords

INTERLEUKIN 1 RECEPTOR; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; INTERLEUKIN 1BETA;

ADULT; ARTICLE; CONTROLLED STUDY; DISEASE PREDISPOSITION; FEMALE; FIBROSING ALVEOLITIS; GENETIC VARIABILITY; GENOTYPE; HUMAN; LUNG LAVAGE; MAJOR CLINICAL STUDY; MALE; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; SINGLE NUCLEOTIDE POLYMORPHISM;

ADULT; AGED; AGED, 80 AND OVER; BRONCHOALVEOLAR LAVAGE FLUID; CYTOKINES; FEMALE; GENETIC VARIATION; GENOTYPE; HUMANS; IDIOPATHIC PULMONARY FIBROSIS; INTERLEUKIN 1 RECEPTOR ANTAGONIST PROTEIN; INTERLEUKIN-1BETA; MALE; MIDDLE AGED; POLYMORPHISM, SINGLE NUCLEOTIDE; RECEPTORS, INTERLEUKIN-1;

EID: 80855144614     PISSN: 00099104     EISSN: 13652249     Source Type: Journal    
DOI: 10.1111/j.1365-2249.2011.04468.x     Document Type: Article

References (28)

1. Mapel DW, Hunt WC, Utton R, Baumgartner KB, Samet JM, Coultas DB. Idiopathic pulmonary fibrosis: survival in population based and hospital based cohorts. Thorax 1998; 53:469-76.
2. Gribbin J, Hubbard RB, Le Jeune I, Smith CJ, West J, Tata LJ. Incidence and mortality of idiopathic pulmonary fibrosis and sarcoidosis in the UK. Thorax 2006; 61:980-5.
3. Rudd RM, Prescott RJ, Chalmers JC, Johnston ID. British Thoracic Society study on cryptogenic fibrosing alveolitis: response to treatment and survival. Thorax 2007; 62:62-6.
4. Kolb M, Margetts PJ, Anthony DC, Pitossi F, Gauldie J. Transient expression of IL-1beta induces acute lung injury and chronic repair leading to pulmonary fibrosis. J Clin Invest 2001; 107:1529-36.
5. Arend WP. Interleukin-1 receptor antagonist. Adv Immunol 1993; 54:167-227.
6. Whyte M, Hubbard R, Meliconi R etal. Increased risk of fibrosing alveolitis associated with interleukin-1 receptor antagonist and tumor necrosis factor-alpha gene polymorphisms. Am J Respir Crit Care Med 2000; 162:755-8.
7. Riha RL, Yang IA, Rabnott GC, Tunnicliffe AM, Fong KM, Zimmerman PV. Cytokine gene polymorphisms in idiopathic pulmonary fibrosis. Intern Med J 2004; 34:126-9.
8. Gasse P, Mary C, Guenon I etal. IL-1R1/MyD88 signaling and the inflammasome are essential in pulmonary inflammation and fibrosis in mice. J Clin Invest 2007; 117:3786-99.
9. Mikuniya T, Nagai S, Shimoji T etal. Quantitative evaluation of the IL-1 beta and IL-1 receptor antagonist obtained from BALF macrophages in patients with interstitial lung diseases. Sarcoidosis Vasc Diffuse Lung Dis 1997; 14:39-45.
10. Heron M, Slieker WA, Zanen P etal. Evaluation of CD103 as a cellular marker for the diagnosis of pulmonary sarcoidosis. Clin Immunol 2008; 126:338-44.
11. de Bakker PI, Yelensky R, Pe'er I, Gabriel SB, Daly MJ, Altshuler D. Efficiency and power in genetic association studies. Nat Genet 2005; 37:1217-23.
12. Hutyrova B, Pantelidis P, Drabek J etal. Interleukin-1 gene cluster polymorphisms in sarcoidosis and idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2002; 165:148-51.
13. Clay FE, Tarlow JK, Cork MJ, Cox A, Nicklin MJ, Duff GW. Novel interleukin-1 receptor antagonist exon polymorphisms and their use in allele-specific MRNA assessment. Hum Genet 1996; 97:723-6.
14. Carter MJ, Jones S, Camp NJ etal. Functional correlates of the interleukin-1 receptor antagonist gene polymorphism in the colonic mucosa in ulcerative colitis. Genes Immun 2004; 5:8-15.
15. Ludwiczek O, Vannier E, Borggraefe I etal. Imbalance between interleukin-1 agonists and antagonists: relationship to severity of inflammatory bowel disease. Clin Exp Immunol 2004; 138:323-9.
16. Barksby HE, Lea SR, Preshaw PM, Taylor JJ. The expanding family of interleukin-1 cytokines and their role in destructive inflammatory disorders. Clin Exp Immunol 2007; 149:217-25.
17. Sekiyama KD, Yoshiba M, Thomson AW. Circulating proinflammatory cytokines (IL-1 beta, TNF-alpha, and IL-6) and IL-1 receptor antagonist (IL-1Ra) in fulminant hepatic failure and acute hepatitis. Clin Exp Immunol 1994; 98:71-7.
18. Aksentijevich I, Masters SL, Ferguson PJ etal. An autoinflammatory disease with deficiency of the interleukin-1-receptor antagonist. N Engl J Med 2009; 360:2426-37.
19. Dionne S, D'Agata DD, Hiscott J, Vanounou T, Seidman EG. Colonic explant production of IL-1 and its receptor antagonist is imbalanced in inflammatory bowel disease (IBD). Clin Exp Immunol 1998; 112:435-42.
20. Cavarra E, Carraro F, Fineschi S etal. Early response to bleomycin is characterized by different cytokine and cytokine receptor profiles in lungs. Am J Physiol Lung Cell Mol Physiol 2004; 287:L1186-L1192.
21. Piguet PF, Vesin C, Grau GE, Thompson RC. Interleukin 1 receptor antagonist (IL-1ra) prevents or cures pulmonary fibrosis elicited in mice by bleomycin or silica. Cytokine 1993; 5:57-61.
22. Wilmott RW, Kitzmiller JA, Fiedler MA, Stark JM. Generation of a transgenic mouse with lung-specific overexpression of the human interleukin-1 receptor antagonist protein. Am J Respir Cell Mol Biol 1998; 18:429-34.
23. Lewthwaite J, Blake S, Thompson RC, Hardingham TE, Henderson B. Antifibrotic action of interleukin-1 receptor antagonist in lapine monoarticular arthritis. Ann Rheum Dis 1995; 54:591-6.
24. Abbate A, Kontos MC, Grizzard JD etal. Interleukin-1 blockade with anakinra to prevent adverse cardiac remodeling after acute myocardial infarction (Virginia Commonwealth University Anakinra Remodeling Trial [VCU-ART] Pilot Study). Am J Cardiol 2010; 105:1371-7.
25. Gauldie J. Pro: inflammatory mechanisms are a minor component of the pathogenesis of idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2002; 165:1205-6.
26. Flaherty KR, Travis WD, Colby TV etal. Histopathologic variability in usual and nonspecific interstitial pneumonias. Am J Respir Crit Care Med 2001; 164:1722-7.
27. Strieter RM. Con: inflammatory mechanisms are not a minor component of the pathogenesis of idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2002; 165:1206-7.
28. Pantelidis P, Fanning GC, Wells AU, Welsh KI, du Bois RM. Analysis of tumor necrosis factor-alpha, lymphotoxin-alpha, tumor necrosis factor receptor II, and interleukin-6 polymorphisms in patients with idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2001; 163:1432-6.